Abstract: The present invention relates to a biodegradable plastic polyhydroxyalkanoate (PHA) composition having improved adhesive properties and mechanical properties, and a method for manufacturing same. Specifically, according to the present invention, it is possible to provide a composition having excellent adhesive properties with respect to a plastic material by improving the adhesive properties by means of a single component of biodegradable PHA without requiring additional chemical substances. In addition, it is possible to provide a composition of which mechanical properties as well as adhesive properties are improved. Therefore, it is possible to manufacture products which are eco-friendly and harmless to the human body, by easily applying the composition to products requiring biodegradable properties along with adhesive properties and mechanical properties.

Abstract: The present invention relates to a polyhydroxyalkanoate (PHA) composition having improved stability and water resistance, and a preparation method therefor. According to the present invention, the aggregation of water-dispersed PHA particles can be prevented, and re-dispersion is induced so that precipitation can be prevented, and thus the dispersion stability and water resistance of PHA can be improved. In addition, the composition of the present invention minimizes the use of additives to enable recycling of biodegradable PHA, and has excellent compatibility with conventional commercial products and excellent room-temperature stability. Additionally, since overuse of a surfactant and an additional step of forming an emulsion are not required in the preparation of PHA, economic feasibility can be improved.

Abstract: A nucleic acid molecule comprising a variant inc coding strand is disclosed as a regulator of plasmid copy number. Also disclosed is a replicon comprising the nucleic acid molecule, a promoter, and an origin of replication. Also disclosed is a vector comprising the replicon. Also disclosed is a recombinant microorganism comprising the vector.

Abstract: A low-temperature processable aliphatic polyester having 3-hydroxybutryates (3HB) and 4-hydroxybutyrates (4-HB) as basic repeated structures and an adjusted content of 4-hydroxybutyrates (4HB) is described. Articles based on the aliphatic polyesters are described and include a biodegradable wax, a medical device, a low-temperature hot melt, a non-woven cloth, a bioplastic, a drug carrier, a medical wrap, a medical fiber, a medical filament, a medical stent, or an orthopedic prosthesis. Methods for preparing the aliphatic polyesters are described.

Abstract: A nucleic acid molecule comprising a variant rpoC coding sequence is disclosed. The variant rpoC coding sequence encodes a variant RpoC which regulates copy number of a plasmid. Also disclosed are a recombinant microorganism comprising the nucleic acid molecule, a method for regulating copy number of a subject vector in the recombinant microorganism, and a method for making a target product by use of the recombinant microorganism.

Abstract: The present invention relates to a low-temperature processible aliphatic polyester and provides a polymer material comprising a polyhydroxyalkanoate copolymer having an adjusted content of 4-hydroxybutyrates (4HB). By utilizing the polymer material according to the present invention, the polymer material can serve as a binder as a short-term biological support, and can be applied as a hot melt material and a non-woven cloth material to impart tacky function to a material that is very sensitive to heat. In addition, the polymer material can be easily applied to various fields.

Abstract: A nucleic acid molecule comprising a variant inc coding strand is disclosed as a regulator of plasmid copy number. Also disclosed is a replicon comprising the nucleic acid molecule, a promoter, and an origin of replication. Also disclosed is a vector comprising the replicon. Also disclosed is a recombinant microorganism comprising the vector.

Abstract: A nucleic acid molecule comprising a variant rpoC coding sequence is disclosed. The variant rpoC coding sequence encodes a variant RpoC which regulates copy number of a plasmid. Also disclosed are a recombinant microorganism comprising the nucleic acid molecule, a method for regulating copy number of a subject vector in the recombinant microorganism, and a method for making a target product by use of the recombinant microorganism.

Abstract: Methods and genetically engineered hosts for the production of 3-carbon, 4-carbon and 5-carbon products, polymers and copolymers in methylotrophic bacteria are described herein.

Abstract: Recombinant hosts for producing polyhydroxyalkanoates and methods of producing polyhydroxyalkanoates from renewable carbon substrates are provided. Certain recombinant hosts that produce 5 carbon chemicals such as 5-aminopentanoate (5AP), 5-hydroxyvalerate (5HV), glutarate, and 1,5 pentanediol (PDO) are also provided. One embodiment provides a recombinant host expressing a gene encoding a heterologous enzyme selected from the group consisting of a polyhydroxyalkanoate synthase and a 5-hydroxyvalerate-CoA (5HV-CoA) transferase, wherein the host produces a polymer containing 5-hydroxyvalerate. Preferably, the host expresses both a polyhydroxyalkanoate synthase and a 5HV-CoA transferase. The host can be prokaryotic or eukaryotic. A preferred prokaryotic host is E. coli. The polymers produced by the recombinant hosts can be homopolymers or copolymers of 5-hydroxyvalerate. A preferred copolymer is poly(3-hydroxybutyrate-co-5-hydroxyvalerate).

Abstract: Methods and genetically engineered hosts for the production of poly-4-hydroxybutrate and 4-carbon products are described herein.

Abstract: The present invention relates to a pharmaceutical combination comprising an alpha-isoform specific phosphatidylinositol 3-kinase inhibitor compound, such as (S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide), or pharmaceutically acceptable salt thereof, and an insulin-like growth factor-1 receptor (IGF1R) inhibitor (e.g., the IGF1R inhibitor ANTIBODY A, or a variant or derivative thereof), a pharmaceutical composition comprising such combination, methods for treating cancer comprising administration of therapeutically effective amounts of such inhibitors to a subject in need thereof, and uses of such combination for the treatment of cancer.

Abstract: The present invention relates to a pharmaceutical combination comprising a MEK inhibitor compound 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide or a pharmaceutically acceptable salt thereof and the IGF1R inhibitor ANTIBODY A, a pharmaceutical composition comprising such combination, methods for treating cancer comprising administration of a therapeutically effective amount of such combination to a subject in need thereof, and uses of such combination for the treatment of cancer.

Abstract: The present invention relates to a pharmaceutical combination comprising an alpha-isoform specific phosphatidylinositol 3-kinase inhibitor compound, such as (S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide), or pharmaceutically acceptable salt thereof, and an IGF1R inhibitor (e.g., the IGF1R inhibitor ANTIBODY A, or a variant or derivative thereof), a pharmaceutical composition comprising such combination, methods for treating cancer comprising administration of therapeutically effective amounts of such inhibitors to a subject in need thereof, and uses of such combination for the treatment of cancer.

Abstract: The present invention relates to a pharmaceutical combination comprising a MEK inhibitor compound 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide or a pharmaceutically acceptable salt thereof and the IGF1R inhibitor ANTIBODY A, a pharmaceutical composition comprising such combination, methods for treating cancer comprising administration of a therapeutically effective amount of such combination to a subject in need thereof, and uses of such combination for the treatment of cancer.

Abstract: Recombinant hosts for producing polyhydroxyalkanoates and methods of producing polyhydroxyalkanoates from renewable carbon substrates are provided. Certain recombinant hosts that produce 5 carbon chemicals such as 5-aminopentanoate (5AP), 5-hydroxyvalerate (5HV), glutarate, and 1,5 pentanediol (PDO) are also provided. One embodiment provides a recombinant host expressing a gene encoding a heterologous enzyme selected from the group consisting of a polyhydroxyalkanoate synthase and a 5-hydroxyvalerate-CoA (5HV-CoA) transferase, wherein the host produces a polymer containing 5-hydroxyvalerate. Preferably, the host expresses both a polyhydroxyalkanoate synthase and a 5HV-CoA transferase. The host can be prokaryotic or eukaryotic. A preferred prokaryotic host is E. coli. The polymers produced by the recombinant hosts can be homopolymers or copolymers of 5-hydroxyvalerate. A preferred copolymer is poly(3-hydroxybutyrate-co-5-hydroxyvalerate).

Abstract: This invention relates to a mutant Escherichia coli SS373 and the production of succinic acid by using the above strain. In detail, a novel E. coli SS373 (W3110 pta::Tn10 ldhA::Km) with the deficiency in the acetate and lactate forming pathways was constructed by genetic engineering technique. An aerobically grown SS373 was then cultured by means of the anaerobic condition shift during the succinate producing stage, which resulted in the efficient production of succinic acid with a higher yield.